Milademetan
As of the edition of 20 October 2026, Milademetan is a small molecule: stopped in 2023; acts on MDM2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Small molecule
- Registered trials
- 13, 9 stopped early
- Disease areas
- Cancer; Blood and lymph; Skin and connective tissue; Digestive system; Immune system; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Milademetan.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MDM2 | E3 ubiquitin-protein ligase Mdm2 | Q00987 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 8 | 4 | 0 | 4 |
| Phase 2 | 4 | 0 | 0 | 4 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 13 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Daiichi Sankyo | Lead sponsor of trials | 2013 to now |
| Pathos AI | Lead sponsor of trials | 2021 to now |